The short version of research chemical fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-15 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
=== Tonus Therapeutics === After completing his formal education, Sachs taught organic chemistry at Chaminade College School followed by a position as a staff fellow at the National Institutes of Health. In 1978, he accepted an assistant professor position in the University at Buffalo's Department of Pharmacology. In this role, Sachs discovered mechanosensitive ion channels which are sensors for systems including the senses of hearing, touch, and balance. As a result of his discovery, he also created the only drug to inhibit these channels. Sachs believed that spider venom could contain molecular compounds that could block the ion channels. After discovering the possibility of a drug, he was contacted by several large pharmaceutical companies but none offered to adopt the drug. He eventually co-launched Rose Pharmaceuticals in 2009, which was named after Sachs’ pet tarantula and grandmother, with a stockbroker named Harvey whose grandson had had Duchenne muscular dystrophy. The following year, the Food and Drug Administration designated the firm’s peptide, called GsMTx4, as an orphan drug for Duchenne muscular dystrophy. In 2012, Sachs and Harvey opened their first-ever headquarters in UB’s New York State Center of Excellence in Bioinformatics and Life Sciences and re-named the company Tonus Therapeutics. Within two years, the company sold the rights to their drug to Akashi Therapeutics. He also began studying AT-300’s effectiveness in dystrophic mice.
=== Hydrolysis === The hydrolysis of nitriles RCN proceeds in the distinct steps under acid or base treatment to first give carboxamides RC(O)NH2 and then carboxylic acids RC(O)OH. The hydrolysis of nitriles to carboxylic acids is efficient. In acid or base, the balanced equations are as follows:
== Production == Lucia Aniello, Paul W. Downs, and Jen Statsky developed the idea for Hacks on a road trip in 2015. The three worked together previously on Broad City, and Aniello and Downs are romantic partners. HBO Max ordered the pilot for Hacks, a single-camera comedy series, from co-creators Aniello, Downs, and Statsky in January 2020, and then picked it up for a 10-episode order in May 2020. The series is co-executive produced with Michael Schur (Fremulon), and David Miner and Morgan Sackett (3 Arts Entertainment). Hacks is produced by Universal Television. On February 8, 2021, Jean Smart and Hannah Einbinder were announced as the two lead cast members and Carl Clemons-Hopkins was announced as a main cast member. Additional recurring cast members were also announced: Kaitlin Olson, Christopher McDonald, co-creator Paul W. Downs, Mark Indelicato, Poppy Liu, Johnny Sibilly, Meg Stalter, and Rose Abdoo. The series premiered on May 13, 2021, with the release of episodes one and two.
== Program structure == Laboratory stewardship programs commonly include four components: governance, interventions, data extraction and monitoring, and review of data coupled with strategies for improvement. Governance generally involves institutional leadership, multidisciplinary committees, laboratory expertise, and support from clinical, quality-improvement, financial, and information-technology personnel. Programs may also establish systems to support the appropriate financial coverage of medically necessary laboratory testing. Data extraction and monitoring can be used to identify patterns of laboratory test utilization, including potential overuse or underuse, and to monitor the effects of stewardship interventions. Monitoring may include test volumes, ordering patterns, costs, the appropriateness of test orders, retrieval of results, and interpretation of results. The resulting data can be reviewed to prioritize opportunities for improvement and guide the selection or modification of stewardship strategies. The design of stewardship programs and their interventions can vary according to institutional priorities, available resources, and clinical setting. Implementation science can be used to identify behavioral and organizational factors that influence laboratory test use and to select interventions appropriate to those factors.
Sources: en.wikipedia.org
(Indeed, testosterone, DHT, and estradiol levels are actually raised by bicalutamide treatment, and for this reason, levels of 3α- and 3β-androstanediol might be elevated to some degree similarly.) These metabolites of testosterone have been found to have AR-independent positive effects on sexual motivation, and may be involved in the preservation of sexual interest and function by bicalutamide and other NSAAs. However, a study found that a combination of bicalutamide and dutasteride, a 5α-reductase inhibitor and inhibitor of neurosteroid biosynthesis, produced fewer sexual side effects than GnRH analogue therapy, specifically suggesting the role of estradiol in the preservation sexual interest and function with bicalutamide monotherapy rather than of DHT metabolites. As an alternative possibility to testosterone metabolites preserving sexual desire and function with bicalutamide, it has been suggested that bicalutamide may not be able to block the actions of androgens in the brain to a degree sufficient to cause substantial sexual impairment.
This indicates that all the protons have been removed. When this is so, the solution is not buffered and the pH rises steeply on addition of a small amount of strong base. However, the pH does not continue to rise indefinitely. A new buffer region begins at about pH 11 (pKw − 3), which is where self-ionization of water becomes important. It is very difficult to measure pH values of less than two in aqueous solution with a glass electrode, because the Nernst equation breaks down at such low pH values. To determine pK values of less than about 2 or more than about 11 spectrophotometric or NMR measurements may be used instead of, or combined with, pH measurements. When the glass electrode cannot be employed, as with non-aqueous solutions, spectrophotometric methods are frequently used. These may involve absorbance or fluorescence measurements. In both cases the measured quantity is assumed to be proportional to the sum of contributions from each photo-active species; with absorbance measurements the Beer–Lambert law is assumed to apply. Isothermal titration calorimetry (ITC) may be used to determine both a pK value and the corresponding standard enthalpy for acid dissociation. Software to perform the calculations is supplied by the instrument manufacturers for simple systems. Aqueous solutions with normal water cannot be used for 1H NMR measurements but heavy water, D2O, must be used instead. 13C NMR data, however, can be used with normal water and 1H NMR spectra can be used with non-aqueous media.
=== Extra-articular === JIA is associated with inflammation in the front of the eye (acute or chronic anterior uveitis), which affects about one in six children with JIA. Eye involvement occurs most commonly in girls, those with only a few joints involved (oligoarthritis), those with rheumatoid factor negative polyarticular JIA, and those with a positive anti-nuclear antibody (ANA). Girls younger than six years old are at greatest risk of anterior uveitis. 90% of chronic anterior uveitis occurs within 4 years of JIA diagnosis. Acute anterior uveitis is seen in 11-13% of JIA and is more commonly associated with the enthesitis related arthritis subtype. It presents with light sensitivity, redness of the eyes and eye pain. Regular eye exams are required for children affected by acute or chronic anterior uveitis related to JIA. Children with the Systemic JIA subtype often experience extra-articular manifestations including fever, rash, enlarged lymph nodes, enlarged liver or spleen, serositis and anemia.
Nitrogen has two stable isotopes: 14N and 15N. The first is much more common, making up 99.634% of natural nitrogen, and the second (which is slightly heavier) makes up the remaining 0.366%. This leads to an atomic weight of around 14.007 u. Both of these stable isotopes are produced in the CNO cycle in stars, but 14N is more common as its proton capture is the rate-limiting step. 14N is one of the five stable odd–odd nuclides (a nuclide having an odd number of protons and neutrons); the other four are 2H, 6Li, 10B, and 180mTa. The relative abundance of 14N and 15N is practically constant in the atmosphere but can vary elsewhere, due to natural isotopic fractionation from biological redox reactions and the evaporation of natural ammonia or nitric acid. Biologically mediated reactions (e.g., assimilation, nitrification, and denitrification) strongly control nitrogen dynamics in the soil. These reactions typically result in 15N enrichment of the substrate and depletion of the product. The heavy isotope 15N was first discovered by S. M. Naudé in 1929, and soon after heavy isotopes of the neighbouring elements oxygen and carbon were discovered. It presents one of the lowest thermal neutron capture cross-sections of all isotopes. It is frequently used in nuclear magnetic resonance (NMR) spectroscopy to determine the structures of nitrogen-containing molecules, due to its fractional nuclear spin of one-half, which offers advantages for NMR such as narrower line width.
The product of this reaction, acetyl-CoA, is the starting point for the citric acid cycle. Acetyl-CoA may also be obtained from the oxidation of fatty acids. Below is a schematic outline of the cycle:
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.